NOVEL ERYTHROPOIETIC AGENTS: A THREAT TO SPORTSMANSHIP

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Medicina Sportiva

• Publication date

  2007-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2478/V10036-007-0007-1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Erythropoietin after a century of research: younger than ever

  2007cited by this paper
• Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients

  2007cited by this paper
• Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo.

  2007cited by this paper
• Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases.

  2007cited by this paper
• Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume

  2007cited by this paper
• Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?

  2007cited by this paper
• No doubt about the validity of the urine test for detection of recombinant human erythropoietin.

  2006cited by this paper
• The prolonged half-lives of new erythropoietin derivatives via peptide addition.

  2006cited by this paper
• False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise.

  2006cited by this paper
• Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.

  2006cited by this paper
• New urinary EPO drug testing method using two-dimensional gel electrophoresis.

  2006cited by this paper
• Effects of recombinant human erythropoietin injections on physical self in endurance athletes

  2006cited by this paper
• Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

  2006cited by this paper
• Biochemistry, Physiology, and Complications of Blood Doping: Facts and Speculation

  2006cited by this paper
• Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.

  2006cited by this paper
• Pitfalls, errors and risks of false-positive results in urinary EPO drug tests.

  2006cited by this paper
• Epoetin delta is effective for the management of anaemia associated with chronic kidney disease*

  2006cited by this paper
• Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production.

  2006cited by this paper
• Quantum chemical modeling of reaction mechanism for 2-oxoglutarate dependent enzymes: effect of substitution of iron by nickel and cobalt.

  2006cited by this paper
• Biosimilar Epoetins: An Analysis Based on Recently Implemented European Medicines Evaluation Agency Guidelines on Comparability of Biopharmaceutical Proteins

  2005cited by this paper
• GASepo - a software solution for quantitative analysis of digital images in Epo doping control

  2005cited by this paper
• Cobalt chloride administration in athletes: a new perspective in blood doping?

  2005cited by this paper
• The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely

  2005cited by this paper
• Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin.

  2005cited by this paper
• Synthetic erythropoietic proteins: tuning biological performance by site-specific polymer attachment.

  2005cited by this paper
• Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

  2005cited by this paper
• Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond.

  2005cited by this paper
• Delivery of an Erythropoietin-Fc Fusion Protein by Inhalation in Humans through an Immunoglobulin Transport Pathway

  2005cited by this paper
• CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.

  2005cited by this paper
• Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease.

  2004cited by this paper
• Training induced effects on blood volume, erythrocyte turnover and haemoglobin oxygen binding properties

  2004cited by this paper
• Upregulation of Endogenous Erythropoietin (EPO) in Healthy Subjects by Inhibition of Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase.

  2004cited by this paper
• Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cells

  2004cited by this paper
• Detection of hemoglobin-based oxygen carriers in human serum for doping analysis: screening by electrophoresis.

  2004cited by this paper
• Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells.

  2004cited by this paper
• Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis.

  2004cited by this paper
• "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable.

  2004cited by this paper
• Detection of hemoglobin-based oxygen carriers in human serum for doping analysis: confirmation by size-exclusion HPLC.

  2004cited by this paper
• New Erythropoietic Proteins: Rationale and Clinical Data

  2004cited by this paper
• Second-generation blood tests to detect erythropoietin abuse by athletes.

  2003cited by this paper
• A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA.

  2003cited by this paper
• Proof of homologous blood transfusion through quantification of blood group antigens.

  2003cited by this paper
• Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid

  2003cited by this paper
• Enhancement of therapeutic protein in vivo activities through glycoengineering

  2003cited by this paper
• Doping: a challenge to the endocrinologist. A reappraisal in view of the Olympic Games of 2004.

  2003cited by this paper
• The antimycotic ciclopirox olamine induces HIF‐1α stability, VEGF expression, and angiogenesis

  2003cited by this paper
• Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures.

  2003cited by this paper
• Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment

  2003cited by this paper
• Cobalt Inhibits the Interaction between Hypoxia-inducible Factor-α and von Hippel-Lindau Protein by Direct Binding to Hypoxia-inducible Factor-α*

  2003cited by this paper
• Design and Chemical Synthesis of a Homogeneous Polymer-Modified Erythropoiesis Protein

  2003cited by this paper
• Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha.

  2003influential reference
• A GATA‐specific inhibitor (K‐7174) rescues anemia induced by IL‐1β, TNF‐α, or l‐NMMA

  2003cited by this paper
• Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803.

  2002cited by this paper
• A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study.

  2002cited by this paper
• Articles on similar topics can be found in the following Blood collections

  2002cited by this paper
• Erythropoietin mimetics derived from solution phase combinatorial libraries.

  2002cited by this paper
• Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine.

  2002cited by this paper
• Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch

  2002cited by this paper
• The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP

  2002cited by this paper
• Antibodies against rHuEPO: native and recombinant.

  2002cited by this paper
• Epoetin omega for treatment of anemia in maintenance hemodialysis patients.

  2002cited by this paper
• Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones.

  2002cited by this paper
• FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.

  2002cited by this paper
• Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA‐2 and NF‐κB

  2002cited by this paper
• A comparison of the physiological response to simulated altitude exposure and r-HuEpo administration

  2001cited by this paper
• Development and characterization of novel erythropoiesis stimulating protein (NESP)

  2001cited by this paper
• Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo.

  2001cited by this paper
• Stimulation of GATA‐2 as a mechanism of hydrogen peroxide suppression in hypoxia‐induced erythropoietin gene expression

  2001cited by this paper
• Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis.

  2001cited by this paper
• Inhibition of prolyl 4-hydroxylase in vitro and in vivo by members of a novel series of phenanthrolinones.

  2001cited by this paper
• An evaluation of the concept of living at moderate altitude and training at sea level.

  2001cited by this paper
• Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin.

  2001cited by this paper
• FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity.

  2001cited by this paper
• Effect of rhEPO administration on serum levels of sTfR and cycling performance.

  2000cited by this paper
• Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen species-independent mechanism.

  2000cited by this paper
• Unusual N-glycosylation of a recombinant human erythropoietin expressed in a human lymphoblastoid cell line does not alter its biological properties.

  2000cited by this paper
• Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans.

  2000cited by this paper
• Recombinant erythropoietin in urine.

  2000cited by this paper
• Molecular and electrical heterogeneity of circulating human erythropoietin measured by sensitive enzyme immunoassay.

  2000cited by this paper
• Improving athletic performance: is altitude residence or altitude training helpful?

  2000cited by this paper
• Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation.

  2000cited by this paper
• Epolones induce erythropoietin expression via hypoxia-inducible factor-1α activation

  2000cited by this paper
• Effects of erythropoietin administration in training athletes and possible indirect detection in doping control.

  1999cited by this paper
• Mimicry of erythropoietin by a nonpeptide molecule.

  1999cited by this paper
• Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins

  1999cited by this paper
• Distribution characteristics of entrapped recombinant human erythropoietin in liposomes and its intestinal absorption in rats.

  1999cited by this paper
• New epoetin molecules and novel therapeutic approaches.

  1999cited by this paper
• An Erythropoietin Fusion Protein Comprised of Identical Repeating Domains Exhibits Enhanced Biological Properties*

  1999cited by this paper
• Negative regulation of the erythropoietin gene expression by the GATA transcription factors.

  1997cited by this paper
• Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity.

  1997cited by this paper
• Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin

  1996cited by this paper
• Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å

  1996cited by this paper
• Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy

  1996cited by this paper
• Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.

  1995cited by this paper
• The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1

  1995cited by this paper
• Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents.

  1995cited by this paper
• Ultrasound-mediated transdermal protein delivery

  1995cited by this paper
• Purification and Characterization of Hypoxia-inducible Factor 1 (*)

  1995cited by this paper
• Detection in blood and urine of recombinant erythropoietin administered to healthy men.

  1995cited by this paper
• Induced erythrocythemia and athletic performance.

  1994cited by this paper

• Final degree project ERYTHROPOIETIN GENE DOPING

  2018cites this paper
• Molecularly Imprinted Polymer-Based Plasmonic Immunosandwich Assay for Fast and Ultrasensitive Determination of Trace Glycoproteins in Complex Samples.

  2016cites this paper
• Hematological Parameters, and Hematopoietic Growth Factors: Epo and IL-3 in Response to Whole-Body Cryostimulation (WBC) in Military Academy Students

  2014cites this paper
• Detection of EPO injections using a rapid lateral flow isoform test

  2013cites this paper
• Detection of recombinant human EPO administered to horses using MAIIA lateral flow isoform test

  2012cites this paper
• Rapid detection of erythropoiesis-stimulating agents in urine and serum.

  2012cites this paper
• Detection of recombinant human EPO and darbepoetin administrated to horses using EPO WGA MAIIA and LC-MS / MS

  2011cites this paper
• Erythropoietin and analogs.

  2010cites this paper
• SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control.

  2009cites this paper
• Hormone abuse in sports: the antidoping perspective.

  2008cites this paper
• Total hemoglobin mass--a new parameter to detect blood doping?

  2008cites this paper
• LC-MS techniques for analytical testing of recombinant human erythropoietin and darbepoetin alfa in equine plasma samples for anti- doping control

  2008cites this paper
• Comments on Lundby et al.'s "testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing". Anti-doping testing: friend or foe?

  2008cites this paper